Fundraising FoxBraidwell — Full Portfolio
10 tracked investments · listed companies and verified rows first
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors.
Ivan Hyep(Chief Financial Officer and Treasurer)inLara Meisner(Chief Legal Officer, Compliance Officer and Corporate Secretary)inDavid Raben(Chief Medical Officer)in
Co-investorsAisling CapitalBioqube VenturesEight Roads VenturesF-Prime CapitalForesite CapitalPremji Invest+6 more
Caris Life Sciences is a precision medicine company focused on molecular profiling and research to support cancer care and improve patient outcomes.
AI & Machine LearningBiotechDigital HealthHealthtechMedical Devices
David Dean Halbert(Chairman, Founder and CEO)
Co-investorsCoatue ManagementJ.H. WhitneyOwl Rock CapitalSilver Lake PartnersSixth StreetMillennium Management+1 more
Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.
BiotechHealthtechNew York, US
Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)inEliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)
Co-investorsBioAdvanceBAM ElevateCommodore CapitalJanus Henderson InvestorsOrbiMedRA Capital+2 more
Encoded develops gene therapies for neurological disorders through an integrated platform approach.
BiotechSouth San Francisco, US
Stephanie Tagliatela(Founder)inKartik Ramamoorthi, Ph.D.(Co-founder, Chief Executive Officer & Board Member)Kartik Ramamoorthi(Founder)
Co-investorsARCH Venture PartnersBioBritGV (Google Ventures)Illumina VenturesMenlo VenturesQuonota Investments+7 more
Impulse Dynamics develops implantable medical device technology for cardiac care, with a background in biomedical research and implantable cardiac electronics.
BiotechHardwareHealthtechMedical DevicesDublin 2, US
Shlomo Ben-Haim(Director)Jason Spees(Chief Executive Officer)inPaul Bae(Chief Administrative Officer and General Counsel)inDavid Prutchi(Executive Vice President, Chief Technology Officer)inRichard J. Buchholz(Chief Financial Officer)Anthony Hong(Chief Science and Strategy Officer)in
Co-investorsAmzak HealthWellington ManagementAlgerEssex Woodlands Healthcare PartnersREDMILESands Capital Ventures+1 more
LILA Sciences builds AI systems for autonomous scientific research and discovery across medicine, materials, energy, and defense sectors.
AI & Machine LearningBiotechDeep TechSaaS
Geoffrey von Maltzahn(CEO)Molly Gibson(Founder)Noubar Afeyan(Founder)
Co-investorsAlumni VenturesCatalio Capital Management, LPDauntless VenturesFlagship PioneeringGeneral CatalystIn-Q-Tel+10 more
.png)
Nabla is a drug development company that applies design discipline and scientific rigor to the development of new medicines.
AI & Machine LearningBiotechDeep TechHealthtechBoston, US
Surge Biswas(Founder)inFrances Anastassacos(Founder)inGeorge M. Church(Founder)Surge Biswas Frances Anastassacos(Founder)
Co-investorsCantos VenturesFifty YearsPetriPillar VCRadical VenturesSparta Group+6 more
Prompt is an Ambient AI product and research company that develops human-centered AI products designed to sense the physical environment.
AI & Machine LearningConsumerDeep TechSan Francisco, US
Tete Xiao(Founder)in
Co-investorsAbstract VenturesAIX VenturesDCVC (Data Collective)Laude VenturesNeotribe VenturesAlexandria+4 more
Proxima develops AI-powered gaming experiences and infrastructure, with a focus on embodied AI agents and applied AI systems for interactive entertainment.
AI & Machine LearningGamingSan Francisco, US
Ran Mo(Founder)in
Co-investorsAIX VenturesKonvoy VenturesProgressionAlexandriaBalderton CapitalBayern Kapital+9 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.